Fabio
8.3 KiB
type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags
| type | title | description | jurisdiction | legislature | session | identifier | citation | classification | subjects | status | primary_sponsors | version_count | action_count | vote_count | first_action | last_action | source | source_identifier | source_url | source_hash | vintage | source_snapshot | retrieved_at | confidence | tags | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bill | Parity for Non-Opioid Pain Management Drugs | The act requires a health insurance carrier that provides prescription drug benefits to require that:The utilization review requirements, including prior authorization and step therapy, for a non-opioid drug prescribed and approved by the federal food and drug administration (FDA) for the treatment or management of chronic or acute pain (non-opioid pain management drug) are no more restrictive than the least restrictive utilization review requirements for opioid drugs prescribed for the treatment or management of chronic or acute pain; andThe cost-sharing, copayment, or deductible for a non-opioid pain management drug is not greater than the cost-sharing, copayment, or deductible for an opioid drug prescribed for the treatment or management of chronic or acute pain. The act requires each individual and small group health benefit plan issued or renewed on or after January 1, 2027, and each large employer health benefit plan issued or renewed on and after January 1, 2028, to ensure there is at least one non-opioid pain management drug available as a clinically appropriate alternative for an opioid pain management drug. If the division of insurance determines that coverage for a non-opioid pain management drug offered by individual and small group health benefit plans requires state defrayal of the cost of coverage, the requirement to make a non-opioid pain management drug available is inoperative. The state employee health benefit plan is excluded from the requirements of the act. The act appropriates $15,415 to the department of regulatory agencies for use by the division of insurance to implement the act.(Note: This summary applies to this bill as enacted.) | us/states/co | Colorado General Assembly | 2026A | SB 6 | Colorado SB 6 (2026A) |
|
|
enacted |
|
7 | 18 | 10 | 2026-01-14 | 2026-06-03 | openstates | ocd-bill/123905d4-412e-4b9e-ab61-b0bb952082d2 | https://leg.colorado.gov/bills/SB26-006 | 7356a035a81430a02e4623091b018b660a08858168240c7b40c56c3782829001 | 2026-07-01 | https://data.openstates.org/daily/2026-07-01/public.pgdump | 2026-07-06 | reported |
|
Colorado SB 6 (2026A) — Parity for Non-Opioid Pain Management Drugs
The act requires a health insurance carrier that provides prescription drug benefits to require that:The utilization review requirements, including prior authorization and step therapy, for a non-opioid drug prescribed and approved by the federal food and drug administration (FDA) for the treatment or management of chronic or acute pain (non-opioid pain management drug) are no more restrictive than the least restrictive utilization review requirements for opioid drugs prescribed for the treatment or management of chronic or acute pain; andThe cost-sharing, copayment, or deductible for a non-opioid pain management drug is not greater than the cost-sharing, copayment, or deductible for an opioid drug prescribed for the treatment or management of chronic or acute pain. The act requires each individual and small group health benefit plan issued or renewed on or after January 1, 2027, and each large employer health benefit plan issued or renewed on and after January 1, 2028, to ensure there is at least one non-opioid pain management drug available as a clinically appropriate alternative for an opioid pain management drug. If the division of insurance determines that coverage for a non-opioid pain management drug offered by individual and small group health benefit plans requires state defrayal of the cost of coverage, the requirement to make a non-opioid pain management drug available is inoperative. The state employee health benefit plan is excluded from the requirements of the act. The act appropriates $15,415 to the department of regulatory agencies for use by the division of insurance to implement the act.(Note: This summary applies to this bill as enacted.)
Version chain
The bill's text revisions, in order — the diff chain from filing to enrollment.
- Introduced (filed) — source
- Engrossed (committee substitute) — source
- Final Act (committee substitute) — source
- Reengrossed (committee substitute) — source
- Rerevised (committee substitute) — source
- Revised (committee substitute) — source
- Signed Act (committee substitute) — source
Votes
- Adopt amendment L.001 (Attachment D). — pass (pass) · upper
- Adopt amendment L.004 (Attachment E). — pass (pass) · upper
- Refer Senate Bill 26-006 to the Committee of the Whole. — pass (pass) · upper
- Refer Senate Bill 26-006 to the Committee on Appropriations. — pass (pass) · upper
- Adopt amendment J.002 — pass (pass) · upper
- BILL — pass (pass) · lower
- REPASS — pass (pass) · lower
- CONCUR — pass (pass) · lower
- Refer Senate Bill 26-006, as amended, to the Committee on Appropriations. — pass (pass) · upper
- Refer Senate Bill 26-006, as amended, to the Committee of the Whole. — pass (pass) · upper
Sponsors
- B. Kirkmeyer — primary (person)
- J. Amabile — primary (person)
- K. Brown — primary (person)
- R. Taggart — primary (person)
- A. Boesenecker — cosponsor (person)
- B. Pelton — cosponsor (person)
- E. Sirota — cosponsor (person)
- J. Bacon — cosponsor (person)
- J. Coleman — cosponsor (person)
- K. McCormick — cosponsor (person)
- K. Wallace — cosponsor (person)
- L. Cutter — cosponsor (person)
- L. Frizell — cosponsor (person)
- L. Smith — cosponsor (person)
- M. Catlin — cosponsor (person)
- M. Duran — cosponsor (person)
- S. Bright — cosponsor (person)
Timeline
The legislative action history — every referral, reading, and vote.
- 2026-06-03 Governor Signed
executive-signature - 2026-05-05 House Second Reading Special Order - Lost with Amendments - Committee
- 2026-05-22 Sent to the Governor
executive-receipt - 2026-05-22 Signed by the Speaker of the House
passage - 2026-05-05 House Second Reading Special Order - Passed with Amendments - No Amendments
- 2026-05-22 Signed by the President of the Senate
passage - 2026-05-08 Senate Considered House Amendments - Result was to Concur - Repass
- 2026-05-06 House Third Reading Passed with Amendments - Floor
passage, reading-3 - 2026-05-05 House Second Reading Special Order - Passed with Amendments - Committee
- 2026-05-01 House Committee on Appropriations Refer Amended to House Committee of the Whole
committee-passage, referral-committee - 2026-04-22 House Committee on Health & Human Services Refer Unamended to Appropriations
referral-committee - 2026-04-20 Introduced In House - Assigned to Health & Human Services
introduction - 2026-04-20 Senate Third Reading Passed - No Amendments
passage, reading-3 - 2026-04-17 Senate Second Reading Special Order - Passed with Amendments - Committee
- 2026-04-17 Senate Committee on Appropriations Refer Unamended to Senate Committee of the Whole
committee-passage, referral-committee - 2026-04-08 Senate Committee on Health & Human Services Refer Amended to Appropriations
referral-committee - 2026-04-02 Senate Committee on Health & Human Services Witness Testimony and/or Committee Discussion Only
- 2026-01-14 Introduced In Senate - Assigned to Health & Human Services
introduction
Source
OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/123905d4-412e-4b9e-ab61-b0bb952082d2. Confidence: reported (aggregated from official Colorado legislature records).